RIZKY SILVIA, 051511133165 (2019) STUDI PENGGUNAAN ANTIAGREGASI PLATELET PADA PASIEN DIABETES MELLITUS TIPE 2 (Penelitian dilaksanakan di Instalasi Rawat Jalan Rumah Sakit Universitas Airlangga Surabaya). Skripsi thesis, Universitas Airlangga.

	Text FF.FK.19-19 Sil s abstrak.pdf Download (197kB)
	Text FF.FK.19-19 Sil s daftar isi.pdf Download (205kB)
	Text FF.FK.19-19 Sil s daftar pustaka.pdf Download (326kB)
	Text (FULLTEXT) FF.FK.19-19 Sil s.pdf Restricted to Registered users only until 19 November 2022. Download (1MB) | Request a copy

Abstract

Based on previous study showed that drug utiliziations of antiplatelet as primary and secondary prevention was lack. Type 2 diabetes mellitus (DM) have a higher risk of cardiovascular disease due to increased platelet reactivity and increased the chance of atherosclerosis. This study aimed to describe the pattern of antiagregation platelet use in type 2 diabetic outpatient. The study was a retrospective study with a total sampling method. Data was taken from the patients medical records who diagnosed with type 2 diabetes mellitus and fullfilled the inclusion criteria, i.e. patients aged ≥ 18 years, with or without using antiplatelet therapy, and with or without any comorbidities. Data were retrieved from January 2nd to December 31st 2018, in the outpatient care unit at Universitas Airlangga Hospital Surabaya. There were 176 patients included in the study of which 58% were female. As much 70 patients received antiplatelet agents, i.e. acetosal, clopidogrel, ticagrelor, cilostazol and a combination of asetosal plus clopidogrel and asetosal plus ticagrelor. The most common antiplatelet therapy used for type 2 diabetic oupatient was acetosal with 80mg once daily and 100mg once daily. Drug-relatedproblems identified were potential drug-drug interactions between acetosal and mefenamic acid, acetosal and meloxicam. Furthermore, a side effect identified was dyspepsia. It can be concluded that antiplatelet therapy was in accordance with the clinical guideline. A prospective study could be conducted to obtain outcome from the longterm use of antiagregation platelet in type 2 diabetes mellitus patients.

Actions (login required)

View Item